Clinical Trial Update: TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial update on recombinant human parathyroid hormone (ALX1-11) assessing fracture incidence in postmenopausal osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• ALX1-11

Snippet

Sponsor: Shire | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED